Frontlight ResearchEarly access
Not yet recruitingPhase 3
Model-informed precision dosing for linezolid: a randomized clinical trial
Key facts
- Who runs it
- University Medical Center Hamburg-Eppendorf
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 30 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adult trial participants a) ≥ 18 years of age b) Linezolid treatment is indicated or has been started due to pneumonia, skin or soft tissue infection; the patient has received no more than 2 infusions of 600 mg linezolid each
- Participation a) with written informed consent of the patient or, Alternatively, but only if the patient is temporarily incapable of giving informed consent b) with written informed consent of his/her legally designated representative or c) after using the option of inclusion via spouse according to § 1358 BGB or d) according to article 35 of the CTR and with obtaining the patients informed consent as soon as possible
- Patients with potential childbearing ability: negative pregnancy test
Who cannot take part
- Concomitant treatment with monoamine oxidase inhibitors (e.g. phenelzine, isocarboxazid, tranylcypromine, moclobemide or selegiline)
- Previous participation in this study
- Infection other than pneumonia, skin or soft tissue infection, especially tuberculosis, endocarditis and osteomyelitis
- Patients whose life expectancy is less than 7 days
- Pregnancy
- Lactation/breastfeeding
- Simultaneous participation or participation in the past 4 weeks in another clinical trial with other medicinal products
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine whether model-informed precision dosing optimizes linezolid dosing in order to better achieve a therapeutic trough concentration compared to standard dosing.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 13 July 2026